+ All Categories
Home > Education > Nanoparticulate drug delivery sysytem

Nanoparticulate drug delivery sysytem

Date post: 15-Apr-2017
Category:
Upload: pravin-chinchole
View: 148 times
Download: 1 times
Share this document with a friend
101
NANOPARTICULATE DRUG DELIVERY SYSTEM Presented by: Chinchole Pravin Sonu (M.PHARM 2 nd SEM) DEPARTMENT OF PHARMACEUTICS & QUALITY ASSURANCE R. C. Patel Institute of Pharmaceutical Education and Research, shirpur.
Transcript
Page 1: Nanoparticulate drug delivery sysytem

NANOPARTICULATE DRUG DELIVERY

SYSTEM

Presented by: Chinchole Pravin Sonu

(M.PHARM 2nd SEM)DEPARTMENT OF PHARMACEUTICS & QUALITY ASSURANCE

R. C. Patel Institute of Pharmaceutical Education and Research, shirpur.

Page 2: Nanoparticulate drug delivery sysytem

Introduction

ס NANOTECHNOLOGY comprises technological developments on the nanometer scale, usually 0.1 to 100 nm. Nanotechnology, the science of the small. Nano is Greek for dwarf, and nanoscience deals with the study of molecular and atomic particles.

The application of nanotechnology in pharmaceutical field includes formulation of Nanoparticles, Nanosuspension, Nanospheres, Nanocapsules, and Nanoemulsion.

NANOSUSPENSIONS : They are colloidal dispersions of nanosized drug particle that are produced by suitable method and stabilized by suitable stabilizer .

NANOPARTICLES : They are solid colloidal particles sized from 30-100 nm . NANOSPHERES : Polymer matrices in which drug is dissolved or dispersed .

NANOCAPSULES : Consists of polymer wall entrapping an oily core in which the drug is dissolved

Page 3: Nanoparticulate drug delivery sysytem

HISTORY -Nanoparticles as a drug delivery vehicle were first developed by Spieser and co-workers in the late 1960s. -In early 1970s the cross linked polyacrylamide nanoparticles were produced. -Scheffel et al. developed a process for production of radiolabelled albumin particles for imaging purpose in nuclear medicines. -Widder et al incorporated magnetic particles into the nanoparticles for targeting of these particles by means of magnetic field.

. NANOPARTICLES : Nanoparticles are particles made of natural or

synthetic polymers ranging in size from 50 to 500 nm. They consist of macromolecular materials in which the active principle ( drug or biologically active material ) is dissolved, entrapped, and or to which the active principle is adsorbed or attached.

Page 4: Nanoparticulate drug delivery sysytem

there are mainly 2 type of nanoparticles NANOPARTICLES

ס Nanospheres are solid core spherical particulates, which

contain drug embedded within the matrix or adsorbed onto the surface.(Matrix type)

Nanocapsules are vesicular system in which drug is essentially encapsulated within the central core surronded by a polymeric sheath.(Reservoir type)

MATRIX type

RESERVIOR type

NANOSPHERES NANOCAPSULES

Page 5: Nanoparticulate drug delivery sysytem

DEFINITION : SUBNANOSIZED STRUCTURES C

CONTAIN DRUG OR BIOACTIVE SUBS. WITHIN THEM

SIZE RANGE : 5nm – 300 nm

Page 6: Nanoparticulate drug delivery sysytem

ADVANTAGES:

IMPROVED EFFICACY REDUCED TOXICITY ENHANCED DISTRIBUTION IMPROVED PATIENT COMPLIANCE

Page 7: Nanoparticulate drug delivery sysytem

EXAMPLE : IN CANCER CHEMOTHERAPY,

CYTOSTATIC DRUGS DAMAGE BOTH MALIGNANT AND NORMAL CELLS ALIKE . BUT NANODRUG DELIVERY SELECTIVELY TARGETS MALIGNANT TUMOR ONLY…..

Page 8: Nanoparticulate drug delivery sysytem

TYPES OF NANOPARTICLES :

1. POLYMERIC NANOPARTICLE2. SOLID LIPID NANOPARTICLE3. NANOSUSPENSION4. POLYMERIC MICELLES5. CERAMIC NANOPARTICLES6. LIPOSOMES7. DENDRIMERS8. MAGNETIC NANOPARTICLES9. NANOSHELLS COATED WITH GOLD10. NANOWIRES11. NANOPORES12. QUANTUM DOTS13. FERROFLUIDS

Page 9: Nanoparticulate drug delivery sysytem

1. POLYMERIC NANOPARTICLES

SOLID COLLOIDAL PARTICLES SIZE : 10 nm – 1000 nm

NANOCAPSULES : DRUG IS IN CAVITY SURROUNDED BY UNIQUE POLYMER MEMBRANE

NANOSPHERES : MATRIX SYSTEM IN C DRUG IS DISPERSED

Page 10: Nanoparticulate drug delivery sysytem

NANOCAPSULE NANOSPHERE

Page 11: Nanoparticulate drug delivery sysytem

Advantages:Small size → Easy penetration

through capillaries → Drug accumulation at target site

Use of biodegradable material for preparation → Sustained drug release

Application :• Controlled & targetted drug

delivery

Page 12: Nanoparticulate drug delivery sysytem

2. SOLID LIPID NANOPARTICLES Colloidal Carrier System

Size : 100 – 500 nm Delivery medium for lipophilic drugs

ADVANTAGES : Good Biocompatibility, low toxicity &

stability

Page 13: Nanoparticulate drug delivery sysytem

3. NANOSUSPENSION Good for poorly soluble drugs Size : 200 – 600 nm Drug powder + surfactant in high

pressure homogenisation → Nanoparticles

Page 14: Nanoparticulate drug delivery sysytem

4. POLYMERIC MICELLES• Miceller systems for systemic delivery of water-insoluble drugs• Amphiphilic copolymer self associate to form micelles in water.• Small size < 100 nm in diameter leads to avoiding of renal excretion and RES• Small size also leads to endothelial cell permeability • Accumulate greatly in tumor cells than in normal

Page 15: Nanoparticulate drug delivery sysytem
Page 16: Nanoparticulate drug delivery sysytem

ADVANTAGES : Better thermodynamic stability in

physiological solution Stable & prolonged systemic

circulation time Rapid invivo dissociation is prevented

Page 17: Nanoparticulate drug delivery sysytem

5. CERAMIC NANOPARTICLES

SIZE : < 50 nm

Ceramic particles with entraped biomolecules

Page 18: Nanoparticulate drug delivery sysytem

ADVANTAGES :Easy preparation process as

similar to sol-gel processNo swelling or porosity changes

with pHProtection for doped molecules

(enzymes , drugs )against denaturation caused by pH & temp.

Compatible with biological systems

Easy conjugation to variety of monoclonal antibodies to target desired sites invivo

Page 19: Nanoparticulate drug delivery sysytem

6. LIPOSOMES Small artificial spherical shape

vesicles Prepared from natural non toxic

phospholiids and cholesterol

Page 20: Nanoparticulate drug delivery sysytem

Classification : Based on size & no. of bilayers ::1. Small unilamellar vesicles [ SUV ] Size : 25-50 nm in diameter2. Large unilamellar vesicles [ LUV ]3. Multilamellar vesicles [ MLV ] Several lipid layers separated by

layer of aq. solution• Drugs in liposomes reduce systemic

toxicity & prevent early degradation• Liposome surface can be modified

by attaching PEG to bilayer to enhance circulation time in blood.

Page 21: Nanoparticulate drug delivery sysytem

7. Dendrimers Tree like molecules with defined

cavities

Page 22: Nanoparticulate drug delivery sysytem

8. Magnetic Nanoparticles• Powerful versatile diagnostic tool in

medicine Use :1. To label sp molecule , cell population

or microorganisms by binding to suitable Ab

2. As contrast agents in MRI3. As a drug delivery mediumMagnetic immunoassay : Magnetic field generated by

magnetically labelled targets is detected by a sensitive magnetometer

Page 23: Nanoparticulate drug delivery sysytem

Composition : Iron oxide [magnetite Fe203 or

maghemite ] coated with polymer such as dextran.

Commercial products :1. Lumiren ( silicon coated iron oxide) Diameter : 300 nm2. Endorem ( dextran coated

magnetite) Diameter : 150 nm

Page 24: Nanoparticulate drug delivery sysytem

9. NANOSHELLS COATED WITH GOLD

Infrared optical activity combine with properties of gold colloid

Consist of :1. Dielectric core ( gold sulfide or

silica or silica ) 2. Metal shell (gold)

Page 25: Nanoparticulate drug delivery sysytem

Particle < 75 nm diameter absorb & others scatter the incidence light

Surface properties of gold nanoshells = gold colloid.

Use : Destroy breast cancer cells Antibodies to breast cancer

can be directly attached to gold nanoshells

Page 26: Nanoparticulate drug delivery sysytem

Nanoshells strongly absorb infrared light while normal tissue is transparent to it

Nanoshell-antibody complex binds only to cancer cells

Infrared laser heats up the nanoshells and thus cancer cells are destroyed.

Page 27: Nanoparticulate drug delivery sysytem

10. Nanowires & Carbon nanotubes Linear nanostructures made from

metals, semiconductors or carbon . Modifications : Single- or multi-walled, Filled or surface

modified Use : Fillers for nanocomposites for

material with sp properties

Page 28: Nanoparticulate drug delivery sysytem

11. NANOPORES

Eg : Aerogel produced by sol-gel chemistry

Applications :1. Catalysis2. Thermal insulation3. Electrode material4. Environment filters5. Controlled release drug carriers

Page 29: Nanoparticulate drug delivery sysytem

12. Quantum Dots Highly light absorbing luminescent

semiconductor nanoparticles Size : 2-8 nm in diameter Luminescence properties of

semiconductor is sensitive to local envrm and nanocrystal surface prepartion.

CdSe-CdS core shell Range : 550nm to 630 nm InP & InAs Range : Near infrared region

Page 30: Nanoparticulate drug delivery sysytem

Fuctionalisation with mercaptoacetic acid or thin silica layer makes it water soluble

Covalent attachment of proteins to mercaptoacetic acid makes it biocompatible

Binding to cell surface, insertion in cell surface & binding to cell nucleii is possible due to conjugation of nanoparticle with targeting protein

Page 31: Nanoparticulate drug delivery sysytem

13. Ferrofluids Colloidal solutions of iron oxide

magnetic nanoparticle covered by polymer layer coated with affinity molecules s/a Ab

Size: 25-100 nm radius Hence they behave as a solution

rather than suspension

Page 32: Nanoparticulate drug delivery sysytem

ADVANTAGES OF NANOSIZING OF DRUGS

Increase surface area Enhances solubility Increase rate of dissolution Increase oral bioavailability More rapid onset of therapeutic

action Decreased dose Decreased patient-to-patient

variability Target specificity Limited side effects

Page 33: Nanoparticulate drug delivery sysytem

Limitations Expensive therapy Excess use of PVA as a detergent

issues with toxicity Limited targeting abilities Discontinuation of therapy is not

possible Conclusion Polymeric systems have great

potential in drug delivery application Still none of this systems is applied in

practice to patients- FDA approval requires extensive toxicity investigations

Page 34: Nanoparticulate drug delivery sysytem

Approaches for the preparation

Page 35: Nanoparticulate drug delivery sysytem

Methods of preparation 1) Amphiphilic macromolecule cross-linking a) Heat cross-linking. b) Chemical cross-linking.

2) Polymerization based methodsa) Polymerization of monomers in situ.b) Emulsion (micellar) polymerization.c) Dispersion polymerization.d) Interfacial condensation polymerization.e) Interfacial complexation.

3) Polymer precipitation methods a) Solvent extraction/Evaporation. b) Solvent displacement (Nanoprecipitation). c) Salting out.

Page 36: Nanoparticulate drug delivery sysytem

PREPARATION METHODS OF NANOPARTICLES

Proteins Gelatin Albumin Lectins Legumin Vicilin

polysaccharides Alginate Dextran Chitosan Agarose Pullulan

(Polymers for nanoparticles)

Page 37: Nanoparticulate drug delivery sysytem

Various synthetic polymers used for prepration of nanoparticles

Prepolymerised Poly(e-caprolactone) Polylactic acid Poly(lactide-co-

glycolide) Polystyrene

Polymerised in process Poly(isobutylcynoacrylate) Poly(butylcynoacrylate) Poly(hexylcynoacrylate) Polymethylmethacrylate

Page 38: Nanoparticulate drug delivery sysytem
Page 39: Nanoparticulate drug delivery sysytem

Polymers used for preparation of nanoparticles& nanocapsules

Polymer use Technique Candidate drugHydrophilicAlbumin, gelatin

Heat denaturation & cross linking in w/o emulsionDesolvation &cross linking in aqueous medium

Hydrophilic

Hydrophilic & protein affinity

Alginate,chitosan Cross linking in aq. medium Hydrophilic & protein affinity

Dextran Polymer precipitation in an organic solvent

Hydrophilic

HydrophobicPoly(alkylcyanoacrylates)

Emulsion polymerizationInterfacial/polymerization

HydrophilicHydrophobic

PolyestersPoly(lactic acid,poly(lactide-co-glycolide)poly(€-caprolactone)

Solvent extraction-evaporationSolvent displacementSalting out

Hydrophilic ,HydrophobicSoluble in polar solventSoluble in polar solvent

Page 40: Nanoparticulate drug delivery sysytem

Method of preparation for nanoparticles

Amphillic macromolecules that undergo a crosslinking reaction during preparation of nanospheres

Monomers that polymerize during formation of nanospheres

Hydrophobic polymers which are initially dissolved in organic solvents & then precipitated under controlled conditions to produce nanospheres

Page 41: Nanoparticulate drug delivery sysytem

Nanoparticles preparation by cross linking of amphiphilic macromolecules

It can be prepared from amphiphilic macromolecules, proteins & polysaccharides which have affinity for aq.&lipid solvents.

The tech.of their preparation involves the aggregation of amphiphiles followed by further stabilization either by heat denaturation or chemical cross linking.

Cross linking in w/o emulsion1. The method involves the emulsification of bovine serum albumin/human

serum albumin or protein aq. solution in oil using high pressure homogenization or high frequency sonication

2. The w/o emulsion so formed is poured into preheated oil. The suspension in preheated oil maintained above 1000C is held stirred for time in order to denature & aggregate the protein contents of aq. pool completely & to evaporate water

3. The particles are finally washed with organic solvent to remove any oil traces & collected by centrifugation

4. The main factors are emulsification energy & temperature (used for denaturation & aggregation

Page 42: Nanoparticulate drug delivery sysytem
Page 43: Nanoparticulate drug delivery sysytem

Phase separation in aqueous medium (desolvation)

The protein or polysaccharide from an aq. phase can be desolvated by PH change or temp change or by adding counter ions. Cross linking may be affected simultaneously or next to the desolvation step

Steps are protein dissolution, protein aggregation & protein deaggregation

Solvent competing agent ,sodium sulphate is mainly used as a desolvating agent while alcohol are added as desolvating or deaggregating agent

Addition can be optimized turbidometrically using Nephelometer.

Page 44: Nanoparticulate drug delivery sysytem

Aqueous phase (Protein aq.solution)

Protein aggregates (coacervates)

Desolvation (solvent competing agent)

Protein colloidal dispersion

Nanoparticle suspension (external aq. Phase)

Crosslinking(aldehyde)

Resolvation(alcohol)

Nanoparticle preparation by desolvation in an aq. medium technique

Page 45: Nanoparticulate drug delivery sysytem
Page 46: Nanoparticulate drug delivery sysytem

PH induced aggregation

Gelatin & Tween 20 were dissolved in aq. phase & PH was adjusted to optimum value. Solutions were heated ,then quenching at 4oC for 24h.The leads to colloidal dispersion of aggregated gelatin. The aggregates were finally cross linked using glutaraldehyde.The size of nanospheres were of 200 nm. The ideal PH range is 5.5-6.5.

Counter ion induced aggregation

Separation of protein phase may occur by the presence of counter ions in the aqueous medium.

The aggregation can be propagated by adding counters ions followed by rigidization step.

Chitosan nanospheres can be prepared by adding tripolyphosphate to the medium.

Alginate nanoparticles can be prepared by gelation with calcium ions

Page 47: Nanoparticulate drug delivery sysytem

Nanoparticles prepared by polymerization methods

The polymers used for nanospheres preparation include poly (methylmethacrylate) poly(acrylamide)poly(butyl cyanoacrylate).

The different methods using in situ polymerization tech. are

Methods in which the monomer to be polymerised is emulsified in a non solvent phase or (emulsion polymerization)

Methods in which the monomer is dissolved in a solvent that is non solvent for the resulting polymer (Dispersion polymerization)

In EP method the monomer is dissolved in an internal phase while in case of DP it is taken in dispersed phase

In both cases after polymerization polymer tends to be insoluble in internal phase & results into suspension of nanospheres

Page 48: Nanoparticulate drug delivery sysytem

Emulsion polymerization Micellar polymerization

The mechanism involved are micellar nucleation & polymerization & homogenous nucleation & polymerization

The first includes swollen monomer micelles as the site of nucleation & polymerization.

The monomer is emulsified in the non solvent phase with the help of

surfactant molecules. The process leads to formation of monomer swollen micelles which has

size in nanometric range.

The polymerization reaction proceeds through nucleation & propogation in the presence of chemical or physical initiator

Page 49: Nanoparticulate drug delivery sysytem
Page 50: Nanoparticulate drug delivery sysytem

Homogeneous polymerization Monomer is sufficiently soluble in the continuous outer phase

Formation of primary chains (oligomers)

At certain length oligomers precipitate & forms primary particles which are stabilized by surfactant

Addition of monomer input or fusion of primary particles forms nanoparticles

Page 51: Nanoparticulate drug delivery sysytem
Page 52: Nanoparticulate drug delivery sysytem

Water soluble drugs may be associated with PACA nanoparticles either by dissolving the drug in the aqueous polymerization medium or by incubating the blank nanospheres with an aq. solution of drug

Drug molecules may be entrapped within the polymer matrix & are also adsorbed onto the surface of nanoparticles

Drug molecules may be physically adsorbed on the surface

Page 53: Nanoparticulate drug delivery sysytem
Page 54: Nanoparticulate drug delivery sysytem

Dispersion polymerization

In emulsion polymerization monomer is emulsified in an immiscible phase using surfactant.In case of dispersion polymerization monomer is dissolved in an aqueous medium which acts as precipitant for polymer

The monomer is introduced into the dispersion medium. Polymerization is initiated by adding a catalyst & proceeds with nucleation phase followed by growth phase.

Page 55: Nanoparticulate drug delivery sysytem

Inverse emulsification polymerization mechanism

Page 56: Nanoparticulate drug delivery sysytem

Emulsion polymerization process

Page 57: Nanoparticulate drug delivery sysytem
Page 58: Nanoparticulate drug delivery sysytem

The nucleation is directly induced in the aqueous monomer solution & the presence of stabilizer or surfactant is not required

The acrylamide or methyl methacrylate monomer is dissolved in aqueous phase & polymerized by gamma irradiation

By chemical initiation (ammonium or potassium peroxodisulphate) combined with heating to temp. above 65 0C

PMMA nanoparticles can be prepared by gamma irradiation in the presence of antigenic material

e.g. influenza virion, influenza sub unit antigen, bovine serum albumin, HIV-1 & HIV-2 antigens

Page 59: Nanoparticulate drug delivery sysytem

Interfacial polymerization

The preformed polymer phase is finally transformed to an embryonic sheath.

The polymer & drug are dissolved in a volatile solvent. The solution is is poured into a non solvent for both polymer & core phase.

The polymer phase is separated as as a coacervate phase at o/w

interface. The mixture turns milky due to formation of nanocapsules.

This method is used for proteins, enzymes, antibodies, & cells

Interfacial polymeric condensation of 2,2-bis-(4hydroxyphenyl) propane & sebacoyl chloride

The size of nanocapsules ranges from 30-300nm

Page 60: Nanoparticulate drug delivery sysytem
Page 61: Nanoparticulate drug delivery sysytem

Nanoparticle preparation using emulsion solvent evaporation method

Page 62: Nanoparticulate drug delivery sysytem

Hydrophobic polymer & or hydrophobic drug is dissolved in a organic solvent followed by its dispersion in a continuous aq. Phase in which the polymer is insoluble. External phase contains stabilizer.

Depending upon solvent miscibility tech.may called as solvent extraction or evaporation method

The polymer precipitation is done by

Increasing the solubility of organic solvent in the external medium by adding an alcohol (isopropanol)

By incorporating water into ultraemulsion(to extract solvent)

By evaporation of solvent at room temp. by using vacuum

Using an organic solvent which is completely soluble in the continuous aq.phase(acetone)nanoprecipitation

Page 63: Nanoparticulate drug delivery sysytem

Solvent extraction method

This method involves the preparation of o/w emulsion

The subsequent removal of solvent or the addition of water to the system so as to affect diffusion of solvent to external phase (emulsification diffusion method)

The solvent used for polymer is poorly miscible with dispersion phase & thus diffuses & evaporates out slowly on continual stirring

Dispersion medium miscible polymer solvent (alcohol & acetone instantaneously diffuses into the aq. phase & polymer precipitates as tiny nanospheres

Page 64: Nanoparticulate drug delivery sysytem

Solvent evaporation method Solvent evaporation done by altering pressure or high speed

homogenization. E.g. Testosterone, Indomethacin.

64

Emulsification

Aqueous phase Distilled water

Surfactant

Solvent evaporation

nanospheres

O/W emulsion

Organic phase Chlorinated Solvent

Polymer

Emulsification solvent evaporation method

Page 65: Nanoparticulate drug delivery sysytem

Solvent displacement method

Page 66: Nanoparticulate drug delivery sysytem

Salting out

Page 67: Nanoparticulate drug delivery sysytem

Solvent displacement method

It is based on interfacial deposition of a polymer following displacement of a semi polar solvent miscible with water from a lipophilic solution

The organic solvent diffuses instantaneously to the external aq. Phase inducing immediate polymer precipitation because of complete miscibility of both the phases

If drug is highly hydrophilic it diffuses out into the external aq. phase while if drug is hydrophobic it precipitates in aq. medium as nanocrystals

Page 68: Nanoparticulate drug delivery sysytem

Solvent displacement method

Page 69: Nanoparticulate drug delivery sysytem

Review on Nanoparticulate carriersNanocarrier system

Preparation method

Polymer/ Lipid based system

Drug Advantage/ Application

Polymeric Solvent evaporation PEG with PEO coating

Protein Fast drug release for 4 hours

nanoparticles Solvent evaporation PLGA Dexamethasone Sustain release for 10 days

nanoprecipitation PLGA Docetaxel Minimized cytotoxicity

Solvent evaporation PLGA-co-PCL Diphtheria toxoid Improved drug uptake

Solid lipid Hot homogenization Stearic acid in 0.1% poloxamer 188

Insulin 80% entrapment efficiency

nanoparticles Emulsion solvent diffusion

Stearic acid in 1% wt/vol aq.PVA

Antitubercular drug Sustained plasma level over 8 day

Magnetic Bottom up fabrication Metallic Fe with activated carbon

Cancer treatment Parenteral administration

nanoparticles Co-precipitation followed by separation

Dextran coated iron oxide

Cancer treatment 74% to 95% drug entrapment

Page 70: Nanoparticulate drug delivery sysytem

Contd.Nanocarrier system

Preparation method

Polymer/lipid based system

Drug Advantage/ Application

Quantum dots Modified one pot method

Positively charged CdTe QD’s

Gene delivery Imaging agents

Colloidal nanosuspension

CdSe-ZnS core shell nanocrystals of QD’s

In-vitro imaging 10% to 20% higher gene silencing activity

Polymeric Co-polymerization Pluronic-PPA micelles

Solid tumor treatment

Increased sol. of hydrophobic drugs

micelles Co-solventevaporation

PEO-PPO-PEO Solid tumor treatment

Minimized cytotoxicity

Nanosized

Colloidal liposome's

Dehydration-Rehydration methods

DOPE-glycol chitosan liposome

Nasal DNA vaccine 53% entrapment efficiency

Suspension and subsequent extrusion

PC/Chol/PEGDSPE Gene delivery Prolonged plasma circulation(24hr)

Page 71: Nanoparticulate drug delivery sysytem

Schematic diagram for the development of targeted nanoparticles

Using a platform technology we first generate an activated nanoparticle. In a second reaction the targeting agent (antibodies) is conjugated to the outer surface of the nanoparticle with the help of Linkers or Spacers.

• The nanoparticle now produced is ready for its specific target.

Page 72: Nanoparticulate drug delivery sysytem

MODE OF ACTION

The targeted nanoparticle finds the specific cellular target.

The nanoparticle binds to the surface of the cell

If the target is internalized (i.e. folate receptors) the nanoparticle

is carried to the intracellular environment

If the target is not internalized (i.e. annexin A2) the delivery

system has been engineered to release the nanoparticle at the

surface of the cell allowing for endocytosis to occur.

Page 73: Nanoparticulate drug delivery sysytem

1) EXHIBIT HIGHER INTRACELLULAR UPTAKE .

2) CAN PENETRATE THE SUBMUCOSAL LAYERS WHILE THE MICROCARRIERS ARE PREDOMINANTLY LOCALIZED ON THE EPITHELIAL LINING .

3) CAN BE ADMINISTERED INTO SYSTEMIC CIRCULATION WITHOUT THE PROBLEMS OF PARTICLE AGGREGATION OR BLOCKAGE OF FINE BLOOD CAPILLARIES . RESTENOSIS

4) THE DEVELOPMENT OF TARGETED DELIVERY IS FIRMLY BUILT ON EXTENSIVE EXPERIENCE IN PHARMACO-CHEMISTRY, PHARMACOLOGY, TOXICOLOGY AND NOWADAYS IS BEING PURSUED AS A MULTI- AND INTERDISCIPLINARY EFFORT .

5) USED FOR SITE SPECIFIC TARGETTING IN VARIOUS CANCER CONDITIONS,GENE THERAPY, .

The potential of Nanocarriers as Drug Delivery Systems.

Page 74: Nanoparticulate drug delivery sysytem

Stimuli that can be utilized to control the behavior and properties of drug delivery systems.

Stimuli Site Stimuli origin

pH

Temperature

Temperature

Magnetic field

Ultrasound

Internal

Internal

External

External

External

Decreased pH in pathological areas, such as tumors, infarcts, and inflammations, because of hypoxia and massive cell death.

hyperthermia associated with inflammation.

Can be caused inside target tissues by locally applied ultrasound or by locally applied high frequency causing the oscillation of target-accumulated magneto-sensitive nanoparticles with heat release.

Magnetic field of different gradients and profiles applied to the body can concentrate magneto-sensitive DDS in required areas.

Sonication can be applied to the body to get a diagnostic signal from echogenic contrast agents and can also facilitate DDS penetration into cells and drug/gene release from ultrasound-sensitive DDS.

Page 75: Nanoparticulate drug delivery sysytem

CHALLENGES

Prevention of drug from biological degradation

Effective Targeting

Patient Compliance

Cost effectiveness

Product life extension

20/03/2008 Dept. of Pharmaceutics 75

Page 76: Nanoparticulate drug delivery sysytem

Where all the action is the

Page 77: Nanoparticulate drug delivery sysytem

Block copolymer micelles for gene therapy

Transfection of plasmid DNA using diblock copolymer.

DNA is released inside the cytosol and appears in the nucleus to express a desired protein.

Page 78: Nanoparticulate drug delivery sysytem

PHARMACEUTICAL ASPECTS OF NANOPARTICLES

The important process parameters performed are Purification, Freeze drying, Sterilization.

1) Purification of nanoparticles:-Toxic impurities includes organic solvents, residual monomers, polymerization initiators, electrolytes, stabilizers & large polymer aggregates. Most commonly used method is gel filtration, dialysis & ultra centrifugation.

But a new methodology called as cross flow filtration method is used.

2) Freeze drying of nanoparticles It includes freezing of nanoparticle suspension & sublimation of water to produce

free flowing powder. Advantages area) Prevention from degradation and/or solubilization of the polymer.b) Prevention from drug leakage, drug desorption, drug degradation.c) Readily dispersible in water without modifications in their physicochemical

properties.

Page 79: Nanoparticulate drug delivery sysytem

Nanocapsules containing oily core may be processed in the presence of mono or disaccharides (glucose or sucrose).

3) Sterilization of Nanoparticles

Nanoparticles for parenteral use should be sterilized to be pyrogen free before animal or human use.

Sterilization in nanoparticles is achieved by using aseptic tech.throughout their preparation & processing & formulation & by sterilizing treatments like autoclaving or gamma- irradiation.

Page 80: Nanoparticulate drug delivery sysytem

Characterization of nanoparticlesParameter Characterization method

Particle size & size distribution Photon correlation spectroscopy,Transmission electron microscopy,Scanning Electron Microscopy,Atomic force microscopy.

Charge determination Laser doppler anemometry, Zeta potentiometer.

Surface hydrophobicity Water contact angle measurements, rose bengal binding X-ray photoelectron spectroscopy

Chemical analysis of surface Static secondary ion mass spectrometry, Sorptometer

Carrier-drug interaction Differential scanning calorimetry

Nanoparticle dispersion stability Critical flocculation temp (CFT)

Release profile In vitro release characteristic under physiologic & sink conditions

Drug stability Bioassay of drug extracted from nanoparticles,Chemical analysis of drug

Page 81: Nanoparticulate drug delivery sysytem

1) Size & morphology EM(SEM & TEM) are widely used for determining particle size & its

distribution. Freeze fracturing of particles allows for morphological determination of

inner structure of particles. TEM permits differentiation among nanocapsules, nanoparticles, &

emulsion droplets Atomic force microscopy (AFM) images can be obtained in an

aq.medium hence used for investigation of nanoparticle behavior in biological environment.

2) Specific surface:- Is determined with the help of Sorptometer. A = 6/ density x D3) Surface charge & electrophoretic mobility:-The nature & intensity of

surface charge determines their interaction with biological environment as well as with bioactive compounds.It is determined by measuring the particle velocity in an electric field. (Laser doppler anemometry)

The surface charge of colloidal particles is measured as electrophoretic mobility which is determined in phosphate saline buffer & human serum

Page 82: Nanoparticulate drug delivery sysytem

4) Surface hydrophobicity:-influences in interaction with biological environment ( Protein particles & cell adhesion).

It is determined by two phase partition,contact angle measurements, adsorption of hydrophobic fluorescent or radiolabelled probes.

X-ray photoelectron spectroscopy permits the identification of specific chemical groups on the surface of nanoparticles.

4) Density:-The density of nanoparticles is determined with helium or air using a gas Pycnometer

5) Molecular weight measurement of nanoparticles:- Molecular weight of the polymer & its distribution in the matrix can be evaluated by gel permeation chromatography using a refractive index detector.

6) Nanoparticle recovery & drug incorporation efficiency:-Nanoparticle yield can be calculated as

nanoparticles recovery(%) = Conc. of drug in nanoparticles *100 conc of nanoparticles recovered

Page 83: Nanoparticulate drug delivery sysytem

7) Drug incorporation efficiency or drug content:-

Drug content(% w/w) = Conc of drug in nanoparticles *100

conc of nanoparticles recovered

8) In vitro release:-In vitro release profile can be determined using standard dialysis, diffusion cell or modified ultrafiltration technique

Page 84: Nanoparticulate drug delivery sysytem

IN VIVO FATE & BIODISTRIBUTION OF NANOPARTICLES

The plasma proteins (opsonins) adsorb on to the surface of colloidal carriers & render particles recognizable to RES.

Phagocytosis of particulates by elements of RES( liver, spleen, bone marrow), liver( Kupffer cells )is regulated by opsonins & dysopsonins (IgA).

SURFACE ENGINEERING OF NANOPARTICLES

1) Stearic stabilized(stealth) nanoparticles2) Biomimetic nanoparticles3) Antibody coated nanoparticles4) Magnetically guided nanoparticles5) Bioadhesive nanoparticles

Page 85: Nanoparticulate drug delivery sysytem

Methods of drug delivery

Page 86: Nanoparticulate drug delivery sysytem

APPLICATIONS OF NANOPARTICLES1) Oral Drug Delivery. Nanosizing of drug lead to dramatic increase in their oral absorption and subsequent bioavailability because of- Increase surface area. Increase saturation solubility. Looareesuwan et al 1999, Atovaquinone an antibiotic indicated for Pneumnocystis carinii showed 2.5 fold increase in oral bioavailability used in the treatment of PCP. Other drugs studied include Danazol, Amphotericin B (kayser et al 2003). 2) Parenteral Drug Delivery. Taxanes has been found useful in the treatment of various cancers .As Taxanes are insoluble in water, TAXOL Nanoemulsion containing Paclitaxel with polyethoxylated castor oil in ethanol was prepared.

A vitamin E-based Nanoemulsion of Paclitaxel (TOCOSOL paclitaxel) was developed by SONUS Pharmaceuticals. It is a Cremophor-free formulation of paclitaxel, a ready-to-use injectable product that incorporates high drug loading (8–10 mg/ml) . Based on the data to date, TOCOSOL paclitaxel shows greater tumor accumulation than Taxol® and antitumor efficacy. TOCOSOL paclitaxel nanodroplets manufactured by proprietary high shearing homogenization have a mean droplet diameter in the range of 40–80 nm, are stable and neutrally charged, which allows for diffusion into the tumor interstitium.

REF; Advances in lipid nanodispersions for parenteral drug delivery and targeting by Panayiotis P. Constantinides, Mahesh V. Chaubal, Robert Shorr. Biopharmaceutical and Drug Delivery Consulting, LLC, Gurnee, IL, USA; Baxter Healthcare, Round Lake, IL, USA.

Page 87: Nanoparticulate drug delivery sysytem

3) Ocular Drug Delivery.Biodegradable as well as water soluble polymer possessing ocular tolerability can be used to sustain the release of the drug.

(Bucolo et al. 2002) successfully formulated FLURBIPROFEN & IBUFROFEN Nanosuspension using acrylate polymers such as Eudragit RS 100 & Eudragit RL 100.

4) Pulmonary drug delivery.Increase adhesiveness of drug to mucosal surface, prolongs the residence time of drug at absorption site.

It offers quick onset of action initially and then control release of active moiety which is required by most pulmonary disorders.

Budesonide is poorly water soluble corticosteroid has been successfully formulated as a Nanosuspension for pulmonary drug delivery.

5) Targeted drug delivery.This system has showed tremendous potential in target drug delivery, especially to brain.

Successful targeting of peptide Dalargin to brain by employing surface modified poly (isobutyl cyanoacrylate) Nanoparticle has been the major achievement in target drug delivery.

Natural targeting of RES by nanosuspension has been already described.Stealth nanoparticles are also produce to avoid RES.

Mucoadhesive bupravaquone nanosuspension reveled 10 fold reductions in infectivity score of Cryptosporidium parvum.

Page 88: Nanoparticulate drug delivery sysytem

Brain targetting BBB is one of the hurdles for the antineoplastics, antibiotics

and neuroleptic agents. Drugs like hexapeptide dalargin, tubocurarine ,doxorubicin

have been targetted by the following approaches1) Higher concentration gradient across the BBB,2) Solubilization of endothelial cell membrane by surfactants,3) Loosening of the tight junction between endothelial cells,4) Endocytosis of nanoparticles and5) Transcytosis of the nanoparticles.

Kreuter and co-workers 1995,reported the transport of the hexapeptide dalargin across the blood-brain-barrier using poly(butylcyanoacrylate) nanoparticles, which were coated with polysorbate80.

Page 89: Nanoparticulate drug delivery sysytem

Enhanced Permeability and Retention (EPR) effect-Nanoparticle entry and accumulation in tumors PEGylated particles, in the desired size range, leaks out of the microvasculature and accumulates into the tumor site.-Insufficient lymphatic drainage favors retention of PEGylated Particles within the tumor site.

Page 90: Nanoparticulate drug delivery sysytem

Various therapeutic applications of nanoparticles /nanocapsules

Application Material Purpose

Cancer therapy Poly(alkylcyanoacrylate)nanoparticleswith anticancer agents,oligonucleotides

Targeting,reduced toxicity, enhanced uptake of antitumour agents, improved in vivo & in vitro stability

Intracellular targeting

Poly(alkylcyanoacrylate)Polyester nanoparticles with anti parasitic or antiviral agents

Target RES for intracellular interactions

Prolonged systemic circulation

Polyesters with adsorbed polyethylene glycols or pluronics

Prolong systemic drug effect,avoid uptake by RES

Vaccine adjuvant Poly (methylmetghacrylate)nanoparticles with vaccines(oral & IM injection)

Enhances immune response

Page 91: Nanoparticulate drug delivery sysytem

Application Material PurposePeroral absorption

Poly(methylmetghacrylate)nanoparticles with proteins & therap.agents

Enhanced bioavailability &protection from GI enzymes

Ocular delivery Poly(alkylcyanoacrylate)with steroids,antiinflammatory agents,antibacterial agents for glaucoma

Improved retention of drugs/reduced wash out

DNA delivery DNA gelatin nanoparticles, DNA chitosan nanoparticles,

Enhanced delivery & higher expression levels

Oligonucleotide delivery

Alginate nanoparticles, poly(D,L)lactic acid nanoparticles

Enhanced delivery of oligonucleotide

Other applications

Poly(alkylcyanoacrylate)nanoparticles with peptidesFor transdermal applicationNanooparticles with radioactive or contrast agentsCopolymerized peptide nanoparticles of n-butyl cyanoacrylate & activated peptides

Crosses blood brain barrier

Improved absorption & permeationEnzyme immunoassays,Radioimaging

Oral delivery of peptides

Page 92: Nanoparticulate drug delivery sysytem

The six major challenge areas of emphasis1. Prevention and Control of Cancer Developing nanoscale devices that can deliver

cancer prevention agents and anticancer vaccines using nanoscale delivery vehicles.

2. Early Detection and Proteomics Creating implantable molecular sensors that can

detect cancer-associated biomarkers(MEMS).3. Imaging Diagnostics

Designing “smart” injectable,targeted contrast agents that improve the resolution of cancer to the single cell level. i.e. Quantum Dots.

Page 93: Nanoparticulate drug delivery sysytem

.

4. Multifunctional Therapeutics Developing nanoscale devices that integrate

diagnostic and therapeutic functions.5. Quality of Life Enhancement in Cancer Care Designing nanoscale devices that can optimally

deliver medications for treating side effects due to chronic anticancer therapy, including pain, nausea, loss of appetite, depression,difficulty in breathing and emesis.

6. Interdisciplinary Training Coordinating efforts to provide cross-training in

molecular and systems biology to nanotechnology engineers and in nanotechnology to cancer researchers.

Page 94: Nanoparticulate drug delivery sysytem

Recent advances An emerging, interdisciplinary science

Integrates chemistry, physics, biology, materials engineering, earth science, and computer science.

The power to collect data and manipulate particles at such a tiny scale will lead toNew areas of research and technology design Better understanding of matter and interactionsNew ways to tackle important problems in healthcare, energy,

the environment, and technologyA most practical applications now, but problems in preparing at

large level.Example : Clottocyte, Respirocyte

Page 95: Nanoparticulate drug delivery sysytem

Artificial platelets (Clottocyte)An artificial mechanical platelet appears to halt bleeding 100-1000 times

faster than natural hemostasis. A single clottocyte, upon reliably detecting a blood vessel break, can rapidly communicate this fact to its neighbors, immediately triggering a progressive controlled mesh-release cascade.

Page 96: Nanoparticulate drug delivery sysytem

Respirocyte The artificial red bloodcellor "respirocyte”

Proposed here is a bloodborne spherical 1-microndiamondoid 1000-atmpressure vessel with active pumping powered by endogenous serum glucose, able to deliver236 times more oxygen to the tissues per unit volume than natural red cells and to manage carbonic acidity.

An onboard nanocomputer and numerous chemical and pressure sensors enable complex device behaviors remotely reprogrammable by

the physician via externally applied acoustic signals.

Page 97: Nanoparticulate drug delivery sysytem

Primary applications will include:1) Transfusable blood substituent's.2) Partial treatment for anemia,3) Perinatal/neonatal and lung disorders;4) Tumor therapies and diagnostics;5) Artificial breathing and6) Prevention of asphyxia.

Page 98: Nanoparticulate drug delivery sysytem

REFERENCES Swarbrick J, Boylan J. Encyclopedia of pharmaceutical technology. 2nd ed.;

Marcel Dekker, New York, 2002, pp : 443.

Targetted and controlled drug delivery, Novel carrier systems; S.P Vyas and R.K.Khar , CBS publishers and distributors, New Delhi, pg no : 331-385.

Pharmaceutical dosage form and drug delivery; Ram I. Mahato, CRC press; pg no : 258-260.

Advances in controlled and novel drug delivery ; Jain N.K. ,CBS publishers and distributors, New Delhi, pg no : 408-426.

www. nanoproject.org

www.nanomanufacturing.eu

NANOPARTICLES & NANOTECHNOLOGY by Dr Paranjothy Kanni*, Health Administrator , Vol : XX, Number 1&2, pg no : 26-28.

Page 99: Nanoparticulate drug delivery sysytem

1) Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles .Journal of Pharmaceutical science 2003; pg no. 409-16.

2) Chen Y, Dalwadi G, Benson H. Drug delivery across the blood-brain barrier. Current Drug Delivery 2004; vol .1, pg no.361-376.

3) Binding and release of drugs into and from thermo sensitive poly(N-vinyl caprolactam) nanoparticles.

* Henna Vihola , Antti Laukkanen , Jouni Hirvonen , Heikki Tenhu . Division of Pharmaceutical Technology, Viikki Drug Discovery Technology Center,

University of Helsinki, PB 56, FIN-00014, Helsinki, Finland. Journal of pharmaceutical science.

4) Colloidal Nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery.

B. Mishra , PhD; Bhavesh B. Patel; Sanjay Tiwari. Department of Pharmaceutics, Institute of Technology, Banaras Hindu University,

Varanasi, India.

Page 100: Nanoparticulate drug delivery sysytem

.

THANK YOU

Page 101: Nanoparticulate drug delivery sysytem

THANK YOU…!


Recommended